Siteman Cancer Center | Strategic Alliance Partners

March 17, 2022

The addition of uproleselan to standard chemotherapy improved improve response rates and reduced chemotherapy-induced mucositis in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia in a phase 1/2 trial.

March 10, 2022

Geoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.

March 09, 2022

Stephen Oh, MD, PhD, discusses current and emerging agents in myelofibrosis, advances in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, updates in acute and chronic graft-vs-host-disease, and chronic lymphocytic leukemia management.

February 24, 2022

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.

February 10, 2022

Brian A. Van Tine, MD, PhD, discusses the methods utilized in the phase 2 Spearhead 1 trial evaluating afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

February 07, 2022

Brian A. Van Tine, MD, PhD, sheds light on the promise of SPEAR T-cell therapy in patients with synovial sarcoma and MRCLS, the safety and efficacy observed with afami-cel in the SPEARHEAD-1 trial, and next steps for research.

November 11, 2021

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.

October 18, 2021

Brad S. Kahl, MD, discusses personalizing frontline treatment in mantle cell lymphoma, clinical trials further examining BTK inhibitors, and research opportunities with CAR T-cell therapy.

October 01, 2021

Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study.

August 24, 2021

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

July 27, 2021

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.

July 07, 2021

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

July 06, 2021

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

May 04, 2021

The addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow transplantation in up to 2 apheresis sessions vs G-CSF alone in patients with multiple myeloma, meeting the primary end point of the phase 3 GENESIS trial.

April 22, 2021

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

April 13, 2021

Ravi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.

November 24, 2020

Nusayba Bagegni, MD, discusses prominent data that have emerged in early-stage and metastatic HER2-positive breast cancer.

November 12, 2020

Nusayba Bagegni, MD, discusses the safety profile of ado-trastuzumab emtansine in early-stage HER2-positive breast cancer.

October 20, 2020

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of oncology.

September 17, 2020

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.